Elevated Serum Soluble Interleukin-2 Receptor Levels Increase Malignancy-related Risk in Patients on Chronic Hemodialysis

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2019 Jun 12

PMID 31183777

Citations 1

Authors

Chen Xiaohong

Shen Bo

Xiang Fangfang

Guo Man

Zou Jianzhou

Liu Zhonghua

Lv Wenlv

Cao Xuesen

Ding Xiaoqiang

Zhang Boheng

Affiliations

Soon will be listed here.

Abstract

Background: Patients on chronic hemodialysis (HD) have an increased incidence of malignancy due to decreased immunity. Soluble interleukin-2 receptor (sIL-2R), as an immunomodulator, seemed to have an effect in the process of malignancy. In this study, we aimed to evaluate the clinical significance of increased sIL-2R in the course of malignancy among HD patients.

Methods: Patients who undergoing chronic hemodialysis were followed for 24 months. Risk factors for malignancy events and malignancy-related mortality during the 2-year follow-up period were investigated among various clinicopathological variables.

Results: Of the 363 patients included in this research, 47 patients (12.95%) had a prior history of treated malignancy. During the 2-year follow-up period, malignancy events were detected in 15 (4.12%) patients. Sixty-seven patients died during the study period, of which nine patients (13.43%) were died of malignancy. Malignancy events reduced 2-year mortality significantly (log-rank = 23.02, P < 0.0001). Both high sIL-2R levels ( ≥ 2-fold upper limit of the normal value) (OR 6.6, P = 0.006) and a prior history of treated malignancy (OR 4.12, P = 0.018)were identified by multivariate logistic analysis as independent determinants for malignancy events. However, only the levels of sIL-2R (used as a continuous variable) had the significantly predictive effect on malignancy events and malignancy-related mortality in the following 2 years.

Conclusions: Elevated sIL-2R levels was commonly seen in serum of HD patients. And this elevated level increased the risk of malignancy. Aside from its role as a biomarker, sIL-2R may also exert biological effects in the course of malignancy.

Citing Articles

Performance of serum soluble interleukin-2 receptor as a diagnostic marker for lymphoma in patients with fever.

Kanda N, Yamaguchi R, Yamamoto Y, Matsumura M, Hatakeyama S Sci Rep. 2023; 13(1):18784.

PMID: 37914769 PMC: 10620379. DOI: 10.1038/s41598-023-44123-5.

References

Maisonneuve P, Agodoa L, Gellert R, Stewart J, Buccianti G, Lowenfels A . Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999; 354(9173):93-9. DOI: 10.1016/s0140-6736(99)06154-1. View

Daichou Y, Kurashige S, Hashimoto S, Suzuki S . Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron. 1999; 83(3):237-45. DOI: 10.1159/000045516. View

Kobayashi H, Tagaya Y, Han E, Kim I, Le N, Paik C . Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2. Cytokine. 2000; 11(12):1065-75. DOI: 10.1006/cyto.1999.0509. View

Wang L, Chow K, Li W, Liu C, Wu Y, Huang M . Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. Clin Cancer Res. 2000; 6(4):1445-51. View

Schiffl H, Lang S, Stratakis D, Fischer R . Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001; 16(9):1863-9. DOI: 10.1093/ndt/16.9.1863. View

Huang A, Quinn H, Glover C, Henderson D, Allen-Mersh T . The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation. Cancer Immunol Immunother. 2002; 51(1):53-7. PMC: 11034347. DOI: 10.1007/s00262-001-0250-6. View

Igney F, Krammer P . Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002; 71(6):907-20. View

Cengiz K . Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol. 2002; 33(1):121-6. DOI: 10.1023/a:1014489911153. View

Chouaib S, Thiery J, Gati A, Guerra N, El Behi M, Dorothee G . Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens. 2002; 60(4):273-81. DOI: 10.1034/j.1399-0039.2002.600401.x. View

10.

Mehta R, Shah G, Adler W, Kittur D . Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients. Clin Transplant. 2004; 18 Suppl 12:67-71. DOI: 10.1111/j.1399-0012.2004.00221.x. View

11.

Murakami S . Soluble interleukin-2 receptor in cancer. Front Biosci. 2004; 9:3085-90. DOI: 10.2741/1461. View

12.

Kuhn D, Dou Q . The role of interleukin-2 receptor alpha in cancer. Front Biosci. 2005; 10:1462-74. DOI: 10.2741/1631. View

13.

Nakase K, Tsuji K, Tamaki S, Tanigawa M, Ikeda T, Miyanishi E . Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev. 2005; 29(3):256-9. DOI: 10.1016/j.cdp.2005.03.001. View

14.

Wang X, Rickert M, Garcia K . Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science. 2005; 310(5751):1159-63. DOI: 10.1126/science.1117893. View

15.

Poggi A, Zocchi M . Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz). 2006; 54(5):323-33. DOI: 10.1007/s00005-006-0038-7. View

16.

Bien E, Balcerska A . Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers. 2007; 13(1):1-26. DOI: 10.1080/13547500701674063. View

17.

Kasprzak A, Olejniczak K, Przybyszewska W, Zabel M . Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol (Warsz). 2007; 66(3):159-66. View

18.

Brivio F, Lissoni P, Fumagalli L, ROVELLI F, Brivio R, Vigore L . Correlation between soluble IL-2 receptor serum levels and regulatory T lymphocytes in patients with solid tumors. Int J Biol Markers. 2008; 23(2):121-2. DOI: 10.1177/172460080802300209. View

19.

de Paiva C, Yoon K, Pangelinan S, Pham S, Puthenparambil L, Chuang E . Cleavage of functional IL-2 receptor alpha chain (CD25) from murine corneal and conjunctival epithelia by MMP-9. J Inflamm (Lond). 2009; 6:31. PMC: 2777897. DOI: 10.1186/1476-9255-6-31. View

20.

Zaoui P, Green W, Hakim R . Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int. 1991; 39(5):1020-6. DOI: 10.1038/ki.1991.129. View